

## ORIGINAL RESEARCH

# Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles

Pande Putu Erawijantari (), <sup>1</sup> Sayaka Mizutani (), <sup>1,2</sup> Hirotsugu Shiroma (), <sup>1</sup> Satoshi Shiba (), <sup>3</sup> Takeshi Nakajima, <sup>4</sup> Taku Sakamoto, <sup>4</sup> Yutaka Saito, <sup>4</sup> Shinji Fukuda (), <sup>5,6,7</sup> Shinichi Yachida (), <sup>3,8</sup> Takuji Yamada (), <sup>1</sup>

► Additional material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ qutjnl-2019-319188).

For numbered affiliations see end of article.

#### Correspondence to

Dr Takuji Yamada, School of Life Science and Technology, Tokyo Institute of Technology, Tokyo 152-8550, Japan; takuji@bio.titech.ac.jp and Professor Shinichi Yachida, Department of Cancer Genome Informatics, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita, Osaka, Japan 565-0871; syachida@cgi.med.osaka-u.ac.jp

Received 29 May 2019 Revised 26 November 2019 Accepted 2 December 2019 Published Online First 16 January 2020

#### Check for updates

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Erawijantari PP, Mizutani S, Shiroma H, *et al. Gut* 2020;**69**:1404–1415.

bsg

## ABSTRACT

**Objective** Recent evidence points to the gut microbiome's involvement in postoperative outcomes, including after gastrectomy. Here, we investigated the influence of gastrectomy for gastric cancer on the gut microbiome and metabolome, and how it related to postgastrectomy conditions.

**Design** We performed shotgun metagenomics sequencing and capillary electrophoresis time-of-flight mass spectrometry-based metabolomics analyses on faecal samples collected from participants with a history of gastrectomy for gastric cancer (n=50) and compared them with control participants (n=56).

**Results** The gut microbiota in the gastrectomy group showed higher species diversity and richness (p<0.05), together with greater abundance of aerobes, facultative anaerobes and oral microbes. Moreover, bile acids such as genotoxic deoxycholic acid and branched-chain amino acids were differentially abundant between the two groups (linear discriminant analysis (LDA) effect size (LEfSe): p<0.05, q<0.1, LDA>2.0), as were also Kyoto Encyclopedia of Genes and Genomes modules involved in nutrient transport and organic compounds biosynthesis (LEfSe: p<0.05, q<0.1, LDA>2.0). **Conclusion** Our results reveal alterations of gut microbiota after gastrectomy, suggesting its association

with postoperative comorbidities. The multi-omic approach applied in this study could complement the follow-up of patients after gastrectomy.

### INTRODUCTION

Recent evidence indicates the involvement of the gut microbiome in disease onset and progression and in postoperative outcome.<sup>1-3</sup> A study on the gut mucosal microbiota following ileocolonic resection for Crohn's disease revealed that microbial community structure was associated with disease recurrence or maintenance of remission.<sup>4</sup> Accordingly, microbiota structure might play a role in clinical outcomes.

Several studies have also highlighted gut microbiota alterations following gastrectomy, which represents the primary treatment for gastric cancer and recently for morbid obesity.<sup>5</sup> <sup>6</sup> Even though the two procedures have different aims, they share similar anatomical and technical features. Several obesity studies indicate that changes in microbial community and functional potential correlate with

## Significance of this study

#### What is already known on this subject?

- Gastrectomy is a surgical treatment for gastric cancer and morbid obesity.
- Gastrectomy alters physiological properties, such as oxygen availability, pH, food transit time, intestinal motility and hormonal conditions.
- Case studies in obesity treatment have shown that faecal microbiome and metabolome alterations persist over time after surgery; in particular, these alterations correlate with metabolic improvements in patients who are morbidly obese.
- Case studies in gastrectomy for gastric cancer using 16S rRNA amplicon sequencing have shown alterations of gut microbiome composition in patients with subtotal gastrectomy.
- Increased risk of developing metachronous colorectal cancer has been reported in patients with gastric cancer.

## What are the new findings?

- The present shotgun metagenomic approach demonstrates overall microbiome community structure changes such as higher abundance of oral microbes, aerobes and facultative anaerobes in faecal samples, which can be related to reconstruction of the GI tract of patients with gastric cancer.
- Gastrectomy-associated alterations in microbial functions, such as nutrient transport and biosynthesis of organic compounds, might relate to changes in postgastrectomy metabolism.
- Several colorectal cancer-related bacteria displayed a similar pattern in postgastrectomy patients: *Fusobacterium nucleatum*, in particular, was significantly enriched (p<0.05) in the total gastrectomy compared with the control group.
- The present metabolomic analysis shows enrichment of deoxycholic acid and branchedchain amino acids in postgastrectomy patients.

weight loss and persistent long-term effects on the gut microbiome.<sup>7–9</sup> Nevertheless, Aron-Wisnewsky *et al* showed that the gut microbiome gene richness



How might it impact on clinical practice in the foreseeable future?

The present study provides novel insights into microbiome/ metabolome features underlying postgastrectomy comorbidities in patients with gastric cancer; in particular, previously reported occurrence of metachronous colorectal cancer following gastrectomy might be associated with alterations of the gut microbiome.

was partially restored 1 year after gastrectomy, in spite of weight loss and improved metabolism.<sup>10</sup>

Gastrectomy as a curative resection for gastric cancer aims to obtain complete histopathological clearance and involves radical resection of the primary site, as well as resection of affected lymph nodes and adjacent organs if necessary.<sup>6</sup> Two studies using 16S rRNA sequencing have reported microbiome alterations after gastrectomy in patients with gastric cancer. Tseng et al revealed that subtotal gastrectomy altered the diversity, community composition and predicted gene functions of gastric microbiota, which associated closely with the altered gastric environment after surgery.<sup>11</sup> Lin et al confirmed these findings by analysing the faecal microbiome over the long term after gastrectomy.<sup>12</sup> They showed that patients with subtotal gastrectomy, and in particular Roux-en-Y gastrojejuno anastomosis, had subsequent lower occurrence of type II diabetes and metabolic syndrome than the controls. However, the possible consequences of microbiota alterations on the patients' condition after gastrectomy, especially total gastrectomy, remain poorly understood.

Increasing evidence indicates a possible link between gut microbiota and postoperative outcome after gastrectomy. For example, patients with gastric cancer could be at an increased risk of developing metachronous cancer including colorectal cancer (CRC) after gastrectomy.<sup>13 14</sup> Because the gut microbiota is known to be associated with CRC, <sup>15–17</sup> it may also affect development of metachronous CRC in postgastrectomy patients. Here, we characterised the faecal microbiome of patients with a history of gastrectomy for gastric cancer and compared them with control participants. To provide a better understanding of microbial metabolism, we complemented these data with metabolome profiles. The study aims to comprehensively characterise the influence of gastrectomy for gastric cancer on the gut microbiome, with the intention of improving nutrition and follow-up examinations in postgastrectomy patients.

### MATERIALS AND METHODS

## Study participants and faecal sample collection

The samples and clinical information used in this study were obtained under conditions of informed consent and with the approval of the institutional review board of each participating institute. A total of 106 participants undergoing total colonoscopy at the National Cancer Center Hospital, Tokyo, Japan, were enrolled. Fifty participants had previously undergone gastrectomy for gastric cancer and did not show signs of gastric cancer recurrence. Those who showed abnormal findings, including precancerous lesions such as adenomatous polyps or carcinomas, were excluded. The remaining 56 participants who did not show any colorectal findings, nor had any history of gastroenterological surgery were included as controls (table 1 and online supplementary tables S1 and S2).

Faecal samples were collected immediately at the first defaecation after starting the oral administration of bowel cleansing

Erawijantari PP, et al. Gut 2020;69:1404–1415. doi:10.1136/gutjnl-2019-319188

agents at the hospital on the day of colonoscopy.<sup>15 18</sup> The samples were placed directly on dry ice and subsequently stored at  $-80^{\circ}$ C for metagenomic and metabolomic analyses. The participants' lifestyle data, including dietary habits and medical records, were acquired from questionnaires (475 questions, 25 pages), based on the example used in the Japan Public Health Center study<sup>19</sup> (online supplementary figure S1A).

## Shotgun metagenomic sequencing and metabolomic quantification

DNA extraction and shotgun metagenomic sequencing of faecal samples (online supplementary methods) generated, on average, 57,888,536 reads per sample and read quality was assessed (online supplementary figure S1B and supplementary table S3). We quantified the metabolites in faecal samples from 44 gastrectomy and 54 control participants using capillary electrophoresis time-of-flight mass spectrometry<sup>20</sup> (online supplementary methods).

### **Taxonomic profiling**

Metagenomic sequencing results were subjected to taxonomic and functional profiling following read quality filtering (online supplementary figure S1B and supplementary methods). Taxonomic profiling using the mOTU pipeline annotated 606 species,<sup>21</sup> whereas 403 species-level clades were obtained using the MetaPhlAn2 pipeline.<sup>22</sup> We categorised the annotated species as oral microbes or others based on the expanded Human Oral Microbiome Database<sup>23</sup> (online supplementary methods). Highlevel phenotypes were identified by BugBase<sup>24</sup> (online supplementary methods).

## **Functional profiling**

Functional profiles were generated using our *in-house* pipeline (online supplementary methods) and the Human Microbiome Project Unified Metabolic AnalysisNetwork 2 (HUMAnN2) pipeline.<sup>25</sup> Annotation results were then summarised into Kyoto Encyclopedia of Genes and Genomes (KEGG) orthology (KO) and KEGG modules<sup>26</sup> profiles (online supplementary figure S1B and supplementary methods). We annotated 498 KEGG modules that collectively contained 6,108 KOs from our *in-house* pipeline. For the HUMAnN2 pipeline, we used UniRef90 as reference and acquired 437 KEGG modules containing 5,971 KOs.

#### Statistical analysis

Low-frequency and less abundant microbial features (species, functional modules and metabolites) were discarded (online supplementary methods). Principal coordinates analysis (PCoA) with Bray-Curtis distance was used to examine the separation of species and metabolites across samples. Permutational multivariate analysis of variance (PERMANOVA) ('adonis' function, vegan package in R) was applied to test microbial composition between groups. Chao1 richness and Shannon-Wiener alpha-diversity index were calculated to estimate microbial diversity between gastrectomy and control groups. Differences in relative abundance of the microbial features were determined by linear discriminant analysis (LDA) effect size (LEfSe)<sup>27</sup> (online supplementary methods).

Associations between microbes, KEGG modules or metabolites and clinical parameters (eg, serum glucose, total cholesterol, body mass index (BMI)) and demographic information (eg, age, gender, smoking habits, alcohol consumption, medical history) were assessed using boosted additive generalised linear models available in the MaAsLin R package<sup>28</sup> (online supplementary methods). Significantly different clinical parameters,

Table 1 Participants' characteristics			
Characteristic	Gastrectomy	Control	P value
Number of participants	50	56	-
Number of participants with metabolite profiles	44	54	-
Gastrectomy type			
Total gastrectomy (n)	12	-	-
Subtotal gastrectomy (n)	38	-	-
Gastrectomy reconstruction (n)			
Stomach-stomach anastomosis	1	-	-
Billroth I	2	-	-
Jejunal interposition	6	-	-
Pylorus-preserving gastrectomy	8	-	-
Roux-en-Y	29	-	-
Time since surgery (median (range) in years)	5 (1–20)	-	-
Age	61.6±10.7	64.0±11.2	0.205
Body mass index (kg/m <sup>2</sup> )	20.6±2.6	23.2±3.0	1.22×10 <sup>-5</sup>
Smokers, n (%)	3 (6.0)	5 (14.3)	0.479
Gender (F/M)	16/34	23/33	0.420
Alcohol consumption (>60 g/day), n (%)	22 (44.0)	31 (55.4)	0.331
Serum glucose (mg/dL)	101.2±12.5	104.6±15.6	0.147
Total cholesterol (mg/dL)	190.4±25.7	209.0±35.8	0.0145
Medications			
Diabetes, n (%)	2 (4.2)	12 (21.8)	0.00889
High blood pressure, n (%)	13 (26.0)	17 (30.4)	0.743
Cholesterol, n (%)	6 (12.0)	10 (17.9)	0.502
Gout, n (%)	0 (0)	2 (3.6)	0.497
Gastric acid suppression, n (%)	4 (8.0)	13 (23.2)	0.0375
Analgesic, n (%)	1 (2.0)	2 (3.6)	1.000
Anticoagulant, n (%)	4 (8.0)	4 (7.1)	1.000
Other, n (%)	8 (16.0)	17 (30.9)	0.108

Statistical test performed: Mann-Whitney U test for numerical data and Fisher's exact test for categorical data; n, number of participants.

F, female; M, male.

demographic characteristics, medical history and diet were tested by a two-sided Mann-Whitney U (MWU) test for numerical data and Fisher exact test for categorical data.

We estimated genus and species association in each group using SparCC<sup>29</sup> (bootstrap n=5000) on selected significantly different genera and species that overlapped between mOTU and Meta-PhlAn2 annotations. Significant co-occurrence and co-excluding interaction (SparCC correlation scores  $\rho < -0.2$  or >0.2 with  $\rho < 0.05$ ) were visualised and analysed using *igraph*. To determine inter-omics (species and metabolome) correlations, we performed Procrustes analysis (online supplementary methods). Additionally, Spearman's correlation analysis was performed on significantly different metabolites and genera to assess their putative correlation (online supplementary methods). Finally, we applied metabolic model-based integration of metabolite observations and species abundances (MIMOSA)<sup>30</sup> to compare the predicted and measured metabolome trends (online supplementary methods).

## RESULTS

# Participants' characteristics and microbial community structure of gastrectomy and control groups

Participants' characteristics did not show significant differences between the gastrectomy (n=50) and control (n=56) groups (table 1 and online supplementary table S1). BMI (two-sided MWU test: p= $1.22 \times 10^{-5}$ ) and total cholesterol (two-sided MWU test: p=0.0145) were significantly lower in the gastrectomy group, although average cholesterol content was within the normal range (128–219 mg/dL) in each group. Preoperational BMI data for 47 (94%) gastrectomy participants indicated lower BMI at the time of faecal sampling (paired sample t-test:  $p=7.00\times10^{-5}$ ) than prior to surgery, suggesting that weight loss could be attributed to postoperative malnutrition, for example, as a result of dumping syndrome.<sup>31</sup> Fifteen postgastrectomy patients (30%) experienced dumping syndrome.

We further examined the influence of gastrectomy on overall microbiome composition and metabolite profiles in faecal samples by performing PERMANOVA with Bray-Curtis distance (figure 1A and B and online supplementary table S4). Species composition differed significantly between the two groups (adonis:  $R^2=0.0369$ ,  $p=9.99\times10^{-4}$ ;  $R^2=0.0387$ ,  $p=9.99\times10^{-4}$ , in mOTU and MetaPhlAn2, respectively). Within-group Bray-Curtis distance was significantly lower in the gastrectomy group than in the control group (two-sided MWU:  $p=5.53\times10^{-7}$ ) (figure 1C). Metabolite profiles were also significantly different between groups (figure 1D) (adonis:  $R^2=0.0647$ ,  $p=9.99\times10^{-4}$ ).

PERMANOVA analysis using different surgery types and reconstructions as predictors (online supplementary results and supplementary table S4) revealed no significantly different microbiome and metabolome distributions across different types of surgery (online supplementary figures S2) except for *Fusobacterium nucleatum*. *F. nucleatum* was highly enriched in total gastrectomy compared with control (LEfSe:  $p=1.53 \times 10^{-5}$ , q=0.00205, LDA=2.87;  $p=4.12 \times 10^{-6}$ ,  $q=3.34 \times 10^{-4}$ ,



**Figure 1** Community structure of the faecal microbiome and metabolome in postgastrectomy and control participants. Principal coordinates analysis (PCoA) with Bray-Curtis distance was performed to assess the community structure of species' relative abundance obtained by mOTU (A) and MetaPhlAn2 (B) in the gastrectomy group (n=50) (orange) and in the control group (n=56) (blue). The PCoA trend was confirmed by significantly lower microbial structure dissimilarity (Bray-Curtis) within groups ( $p=5.53 \times 10^{-7}$ ) (C). PCoA was performed also on faecal metabolite concentrations in the gastrectomy group (n=44) (orange) and the control group (n=54) (blue) (D).

LDA=1.43, in mOTU and MetaPhlAn2, respectively) and subtotal gastrectomy group (LEfSe:  $p=5.58 \times 10^{-5}$ , q=0.0150, LDA=2.34;  $p=1.45 \times 10^{-5}$ , q=0.00366, LDA=2.14, in mOTU and MetaPhlAn2, respectively) (online supplementary results and supplementary table S5). Owing to an unbalanced sample size, statistical power may have been insufficient to detect microbiome and metabolome differences across different reconstructions; however, we could clearly observe a different distribution pattern of predominant species and metabolites (online supplementary results and supplementary figures S3 and S4).

To examine the possible confounding effects of clinical parameters (eg, BMI, serum glucose, total cholesterol), demographic data (eg, age, gender) and medical history (eg, medication, diseases), we performed PERMANOVA and MaAsLin. PERMANOVA showed that the participants' grouping explained the variance in species composition and metabolite profiles better than any of the other predictors (online supplementary results and supplementary rable S4). MaAsLin indicated that the association coefficients were not meaningfully affected by adjustment for possible confounders (online supplementary figure S5).

Underlying comorbidities and concurrent medication of the participants may influence gut microbiota. The number of participants using gastric acid secretion inhibitors and diabetes therapeutic drugs varied significantly between the gastrectomy and control groups. Statistical analyses on subsets of the original participants that excluded such users confirmed the lack of any effect of the exclusion on originally reported gastrectomyenriched microbiome and metabolome signatures (online supplementary results and supplementary tables S6 and S7). The microbial features that were significantly enriched (LEfSe: p<0.05, q<0.1, LDA>2.0) in control individuals who took gastric acid secretion inhibitors or diabetes therapeutic drugs are also reported (online supplementary results and supplementary tables S8 and S9).

## Microbial diversity and richness are higher in gastrectomy patients

The gastrectomy group showed higher Chao1 index (mOTU:  $p=4.64 \times 10^{-4}$ ; MetaPhlAn2:  $p=1.93 \times 10^{-6}$ ) (figure 2A and B) and Shannon diversity index (mOTU: p=0.0954; MetaPhlAn2: p=0.0104) (figure 2C and D) for species composition than their control counterparts. Higher Shannon diversity indices were conserved across the three major phyla: Firmicutes (mOTU:  $p=8.98 \times 10^{-7}$ ; MetaPhlAn2:  $p=2.91 \times 10^{-4}$ ), Actinobacteria (mOTU:  $p=7.69 \times 10^{-4}$ ; MetaPhlAn2: p=0.0419) and Bacteroidetes (mOTU: p=0.225; MetaPhlAn2: p=0.0283) (figure 2E and F). Our results were in accordance with previous studies, in that species diversity was higher in patients with postgastrectomy gastric cancer<sup>12</sup> and obesity<sup>9 32 33</sup> than in non-surgical participants.



**Figure 2** Microbiome diversity in gastrectomy and control groups. Species richness was measured using the Chao1 index calculated from the species annotated by mOTU (A) and MetaPhIAn2 (B). Species alpha-diversity was measured using the Shannon-Wiener index based on mOTU (C) and MetaPhIAn2 (D) annotation. Species alpha-diversity was measured for each major phylum using mOTU (E) and MetaPhIAn2 (F) annotation.

**Postgastrectomy patients exhibit a distinct faecal microbiota** Several taxa, mostly Bacilli, were significantly enriched in the gastrectomy group compared with controls (LEfSe: p<0.05, q<0.1, LDA>2.0) (figure 3A and B). Bacilli were previously reported to be enriched in the gut<sup>12</sup> and gastric microbiota of patients after gastrectomy for gastric cancer.<sup>11</sup> In obesity cases, Bacilli can be used to discriminate between postgastrectomy patients and non-surgical controls.<sup>32</sup>

The mOTU annotation identified 89 species (online supplementary table S10), whereas MetaPhlAn2 annotation identified 76 species (online supplementary table S11) that differed significantly between gastrectomy and control groups (LEfSe: p < 0.05, q < 0.1, LDA>2.0), whereas 39 species overlapped between the two methods. The predominant species in postgastrectomy patients were *Streptococcus* (six species), followed by *Prevotella* (four species) and *Veillonella* and *Lactobacillus* (three species, each). Based on MaAsLin analysis of species composition with clinical parameters, enrichment of *Roseburia hominis* and *Ruminococcus gnavus* might be affected by BMI (online supplementary results and supplementary tables S10 and S11). None of the differentially enriched species exhibited significant associations with serum glucose or total cholesterol (MaAsLin: p > 0.05, q > 0.1).

Oral microbes (eg, *Streptococcus*, *Veillonella*, *Prevotella*) were relatively more abundant (two-sided MWU test: p<0.01) in the gastrectomy group (figure 3C and D), as did also aerobes and facultative anaerobes based on phenotype prediction (figure 3E and F, MWU:  $p=6.43 \times 10^{-7}$ , p=0.0337, respectively).

#### Gastrectomy alters microbial functional characteristics

To examine the functional consequences of microbial community changes, we annotated 73 KEGG modules (based on our *in-house* pipeline) and 119 KEGG modules (based on the HUMAnN2 pipeline) that were differentially abundant (LEfSe: p<0.05, q<0.1, LDA>2.0) between the gastrectomy and control groups (online supplementary table S12 and supplementary figure S6). Among the KEGG modules identified as differentially abundant by both pipelines were those for membrane transport, biosynthesis of organic compounds, multidrug resistance, two-component regulatory system (TCS) and others (figure 4A). In the membrane transport system, phosphate and several amino acid transporters were particularly enriched in the gastrectomy group, followed by manganese/iron and vitamin B<sub>12</sub> transporters. Our results were in agreement with those reported in a previous obesity study.<sup>9</sup> On the contrary, modules involved



**Figure 3** Differential enrichment of microbes in gastrectomy and control groups. Cladogram of species annotated by mOTU (A) and MetaPhlAn2 (B). Each dot represents a taxonomic hierarchy. Dots are marked for significant (LEfSe: p<0.05, q<0.1) enrichment either in the gastrectomy group (n=50) (orange) or in the control group (n=56) (blue). Taxa that reached a linear discriminant analysis score (log10) >3.0 are highlighted and labelled accordingly. The summed relative abundances of oral microbes were compared between the gastrectomy (n=50) and control (n=56) groups based on the species annotated by mOTU (C) and MetaPhlAn2 (D). The summed relative abundances of aerobes (E) and facultative anaerobes (F) were compared between the two groups.

in raffinose/stachyose/melibiose transport, along with isoleucine and cobalamin (vitamin  $B_{12}$ ) biosynthesis, were enriched in the controls. We also observed significantly higher abundance of modules related to TCS and multidrug resistance in the gastrectomy group. KEGG modules' association with the participants' demographic characteristics revealed that control or gastrectomy group classification had a predominant impact on module composition (MaAsLin: p<0.05, q<0.1, online supplementary table S12). To compare module composition between gastrectomy and control groups, we estimated species richness (Chao1) and alpha-diversity (Shannon-Wiener) of each module contributor previously confirmed by our *in-house* and HUMAnN2 pipelines based on the HUMAnN2 output (online supplementary table S13). The three most abundant modules in the control group, raffinose/stachyose/melibiose transport system (M00196), isoleucine biosynthesis (M00535) and cobalamin biosynthesis (M00122), had significantly higher species diversity and



**Figure 4** Different trends of functional modules and metabolites from the faecal microbiomes of gastrectomy and control groups. Relative abundance and linear discriminant analysis (LDA) score (log10) of Kyoto Encyclopedia of Genes and Genomes (KEGG) modules annotated by the Human Microbiome Project Unified Metabolic Analysis Network 2 (HUMANN2) and overlapping with those annotated by our *in-house* pipeline (linear discriminant analysis effect size (LEfSe): p<0.05, q<0.1, LDA>2.0) (A). Richness (Chao1) and alpha-diversity (Shannon-Wiener) of contributor species were estimated. Three modules (marked by an asterisk (\*) in A) contributed by significantly more diverse and richer microbes (two-sided Mann-Whitney U test (MWU): p<0.001) in the gastrectomy group, in spite of their enrichment in the control group (B). The modules were M00196, M00535 and M00122 (two-sided MWU:  $p=5.31\times10^{-4}$ ,  $3.17\times10^{-5}$ ,  $7.14\times10^{-6}$ , for richness, respectively, and  $p=1.12\times10^{-4}$ ,  $2.22\times10^{-4}$ ,  $6.10\times10^{-4}$ , for alpha-diversity, respectively). KEGG modules' relative abundance is represented by the top value of each stack of bars. Samples were subsequently sorted according to the dominant contributor to a module and then grouped as either gastrectomy or control (sample order differs between panels). Different trends in metabolites were also observed between the two groups (LEfSe: p<0.05, q<0.1, LDA>3.0) (C). Bile acid reaction consisted of deconjugation of conjugated bile acids (glycocholate and taurocholate) into their primary form (cholate) and amino acids (glycine and taurine) followed by  $7 \cdot \alpha / \beta$ -dehydroxylation to form secondary bile acids (deoxycholic acid (DCA)). The colours highlight enrichment in the control (blue) and gastrectomy (orange) groups (D).

richness in the gastrectomy group (figure 4B and online supplementary table S13). Whereas the dominant species were identical among the two groups, their proportions were different. For example, *Bacteroides vulgatus* contributed predominantly to cobalamin biosynthesis in both groups; however, *Escherichia coli* was a major module contributor in the gastrectomy group (figure 4B). We also detected three different microbes' groups that contributed to the enrichment of three different KEGG modules involved in manganese/iron/zinc/copper transport (online supplementary figure S7). Overall, these findings indicate a microbial community-level shift followed by an alteration in functional potential.

#### Metabolome profiles change in postgastrectomy patients

We observed different enrichment of metabolites between control (n=54) and gastrectomy (n=44) participants (figure 4C) (52 vs 46 metabolites, respectively; LEfSe: p<0.05, q<0.1, LDA>2.0, online supplementary table S14). Specifically, primary (cholate) and conjugated forms of bile acids (taurocholate and glycocholate) were more abundant in the control group, whereas the secondary form (deoxycholic acid (DCA)) was significantly more abundant in the gastrectomy group (figure 4C and D). Twelve amino acids, including all branched-chain amino acids and two aromatic amino acids (Ile, Leu, Val, Tyr, Phe), were significantly enriched in the gastrectomy group. Metabolites' association with the participants' demographic parameters by MaAsLin showed that cholate enrichment in the control group might be affected by BMI, whereas phenyl-lactate and arginine enrichment might be affected by total cholesterol (online supplementary results and supplementary table S14).

## Putative microbes-microbes and microbes-metabolites correlations in each group

Given the notably distinct microbiome composition between gastrectomy and control groups, we compared the topology of genus (figure 5A and B) and species (online supplementary figure S8) co-occurrence and co-excluding networks. In the genus network, the number of edges was higher in the control group (co-occurrence, 25; co-excluding, 15) compared with the gastrectomy group (co-occurrence, 9; co-excluding, 9). Although the edges do not necessarily represent ecological interactions (eg, mutualism, competition), the microbial network can show which organisms form the hub of community composition.<sup>34</sup> Most close relationships ( $\rho$ >0.6) in the control group (eg, Coprobacillus, Eggerthella) did not appear or showed much lower values (0.2 <  $\rho$  < 0.4) in the gastrectomy group. In this group, Veillonella contributed to most connections (six genera), but co-excluded ( $\rho < -0.3$ ) with four genera including Coprococcus ( $\rho = -0.569$ ,  $p = 4.00 \times 10^{-4}$ ) and Odoribacter  $(\rho = -0.384, p = 0.0160)$  (online supplementary table S10e). That might reflect the role of Veillonella as a network-hub in the gastrectomy group and its importance in microbial community alteration.<sup>34</sup> Results were similar at species level, whereby co-occurrence networks were more abundant in the control (co-occurrence, 31; co-excluding, 8) compared with the gastrectomy group (co-occurrence, 25; co-excluding, 1). Several co-occurrence and co-excluding patterns were shared among genus-level and species-level networks (online supplementary results and supplementary figure S8).

Next, we examined microbiome and metabolite correlations. Procrustes analysis showed an overall significant inter-omics relationship between metabolites and species (mOTU: r=0.279, p=0.003, online supplementary figure S9D; MetaPhlAn2:

r=0.292, p=0.002, online supplementary figure S9E). Bi-clustering of correlations between significantly different genera (LEfSe: p<0.05, q<0.1, LDA>2.0, by mOTU and MetaPhlAn2 annotation) and metabolites (LEfSe: p<0.05, q<0.1, LDA>3.0) revealed distinct clusters (figure 5C). Positive correlation clusters were observed in gastrectomy-enriched metabolites and genera, as well as in control-enriched metabolites and genera. Control-enriched clusters included positive correlations between primary and conjugated bile acids (eg, cholate, taurine, glycocholate) and *Coprobacillus, Blautia, Eggerthella* and *Bifidobacterium*. In contrast, DCA exhibited a significantly positive correlation with *Alistipes, Odoribacter, Lactobacillus* and *Coprococcus*, which were mutually enriched in gastrectomy patients.

The limited fraction of species contributing to metabolome data (134 out of 326 detected metabolomes) was predicted using MIMOSA based on the KEGG reactions information (online supplementary table S15, supplementary figure S10). In particular, the genus *Roseburia* contributed to the metabolism of bile acids-related metabolites (eg, glycocholate, taurine, cholate) (figure 5C). *Roseburia* was enriched in the gastrectomy group and showed a negative correlation with bile acid metabolites that were enriched in the control group. The prediction indicated a consistent contribution of *Roseburia* to the degradation of those metabolites.

Four (Leu, Ile, Ala, Val) out of nine amino acids formed a cluster and exhibited significant positive correlation with *Atopobium, Veillonella* and *Streptococcus*, which were mutually enriched in postgastrectomy patients. *Streptococcus* and *Veillonella* have been reported to ferment amino acids.<sup>35</sup> We also observed the contribution of several gastrectomy-enriched species to amino acids synthesis (eg, *Bacteroides fragilis*) or degradation (eg, *Akkermansia muciniphila*) (online supplementary table S15). Accordingly, a gastrectomy-associated increase in the availability of amino acids might lead to more amino acid fermentators.

#### DISCUSSION

Gastrectomy followed by reconstruction of the GI tract radically alters oxygen availability, gut pH, food transit time, intestinal motility and hormonal conditions.<sup>36 37</sup> We hereby show that gastrectomy for gastric cancer affects also the faecal microbiome and metabolome. Their links to physiological alterations are summarised as a schematic hypothesis (figure 6). Community PCoA highlighted species-level differences in microbiome composition and metabolite profiles between gastrectomy and control groups. The dissimilarity index within the gastrectomy group was significantly lower than in the control counterpart, demonstrating greater species similarity among postgastrectomy individuals (figure 1).

Higher species richness and diversity in postgastrectomy patients (figure 2) confirms previous reports on both gastric cancer<sup>12</sup> and obesity.<sup>9 32 33</sup> This trend might be explained by a combination of major alterations in the gut environment that could support growth of several microbes. One such change is the presence of more oxygen in the gut after gastrectomy,<sup>38</sup> which may provide a preferable niche for aerobic and facultative anaerobic microbes.<sup>7 9 32</sup> Indeed, relative abundance of aerobes (*Streptococcus* and *Enterococcus*) and facultative anaerobes (*Escherichia, Enterobacter* and *Streptococcus*) was higher in postgastrectomy patients compared with control participants (figure 3E and F).

Another possibility might be the migration of oral microbes into the gut. Several microbes frequently detected in the oral Stomach



**Figure 5** Genus-genus and genus-metabolite correlations. Co-occurrence (red) and co-excluding (green) relationships between genera (SparCC:  $-0.2 < \rho < 0.2$ , p < 0.05) in gastrectomy (n=50) (A) and control (n=56) (B) groups. The edge width corresponds to SparCC correlation coefficients. The nodes' size is scaled based on the genus relative abundance averaged over participants within each group. Nodes' colour represents enrichment of the genus in gastrectomy (orange) and control (blue) participants. Spearman's correlation analysis was performed between differentially abundant genera (linear discriminant analysis effect size (LEfSe): p < 0.05, q < 0.1, linear discriminant analysis (LDA)>2.0) and metabolites (LEfSe: p < 0.05, q < 0.1, LDA>3.0) from gastrectomy (n=44) and control (n=54) participants (C). The matrices were derived from Euclidean distance-based bi-clustering of Spearman's RANK correlation coefficients in each square represent positive (red) and negative (blue) relationships. Colours are proportional to the absolute value of Spearman's RANK correlations (see legend in the figure). Statistically significant correlations (p < 0.05, q < 0.1) are marked with asterisks (\*). Correlations confirmed by Model-based Integration of Metabolite Observations and Species Abundances are marked by a rectangle (see legend in the figure).



**Figure 6** Data integration-derived schematic hypothesis. Schematic hypothesis of gut microbiome and metabolite alterations after gastrectomy. The scheme is divided into three parts denoting physiological changes (grey), findings from our study (blue) and the possible consequences (red). Solid lines show the links confirmed by previous studies. Dashed lines show possible connections that can be inferred from our findings. The higher or lower levels observed in postgastrectomy patients are shown in comparison with those of control participants. BCAA, branched-chain amino acids.

ecosystem<sup>23</sup> were significantly more abundant in postgastrectomy patients (figure 3C and D). They included several species of the genera *Streptococcus*, *Veillonella* and *Prevotella* (online supplementary tables S10 and S11). *Veillonella*, in particular, formed a network-hub in the gastrectomy group, suggesting an important role in microbial community alteration (figure 5A and B, and online supplementary figure S8). Interestingly, *F. nucleatum* was significantly enriched in the total gastrectomy group (n=12), compared with control (n=56) and subtotal gastrectomy (n=38) counterparts. The intestinal tract sustains lower acidity due to reduced gastric acid secretion following gastrectomy.<sup>23 32</sup> These results indicate that gastrectomy promotes higher transport and survival, as well as growth of aerobes, facultative anaerobes and oral microbes in the distal GI tract.<sup>9 32 33</sup>

Previous studies indicated that stomach reconstruction affected microbial functions in the gut.<sup>9-11 32</sup> Metagenome-based functional analysis revealed gastrectomy-associated enrichment of KEGG modules related to nutrient transport system, including manganese/iron/zinc/copper and vitamin  $B_{12}$ . The obesity study suggested that this feature could reflect the increased availability of those substances to microbes.<sup>9</sup> Here, no significant difference in dietary consumption was observed between the control and gastrectomy groups (online supplementary table S16).

Regarding postoperative metabolism, several studies have reported nutrient intolerance (eg, dumping syndrome) and nutrient deficiency (eg, anaemia) in gastrectomy patients, which could be attributed to malabsorption, impaired food intake and altered transit time, and result in weight loss.<sup>31 39</sup> The observed postoperative reduction in BMI might be associated with these metabolic deficiencies; however, we did not observe any microbiome or metabolites associated with patients having dumping syndrome (online supplementary results and online supplementary table S17). Furthermore, gastrectomy-associated enrichment of microbial nutrient transport might be associated with the host metabolic functions in two ways. First, postsurgical metabolic deficiencies are at least partially attributed to alterations in gut microbial function (figure 4B and online supplementary figure S7). Second, these changes might be associated with the impaired metabolism of the host. For example, enrichment of the vitamin B<sub>12</sub> transporter (M00241) in the gastrectomy (online supplementary table S12) and particularly total gastrectomy group (online supplementary table S5) might be related to the malabsorption of vitamin B<sub>12</sub>. This may follow from inadequate secretion of intrinsic factors and reduced gastric acidity in the stomach, which causes a lack of absorption in the terminal ileum following gastrectomy.<sup>40</sup> Consequently, vitamin  $B_{12}$  that remain unabsorbed in the colon and lead to more microbes with high vitamin B<sub>12</sub> intake capacity.<sup>41</sup> In the present study, we observed that the vitamin  $B_{12}$  biosynthesis module (M00122) was enriched in the control group. Further comprehensive analysis including the effect of preoperative and postoperative supplemental diet could help decipher these mechanisms.

The present faecal metabolomic analysis also showed that DCA, one of the secondary bile acids, was enriched in postgastrectomy patients, while other forms, such as conjugated and primary bile acids, were enriched in the control counterparts (figure 4C and D). This might be explained by alterations in bile flow after gastrectomy stimulating the growth of bile acid-transforming bacteria. These bacteria play a key role in the deconjugation or transformation of bile acid to secondary bile acids.<sup>32 42</sup> The process is typically mediated by a 7-α/β-dehydroxylation enzyme, expressed by specific members of *Clostridium* and *Eubacterium* in the human large intestine.<sup>42 43</sup> Although not significant, we confirmed that *Clostridium* and *Eubacterium* genera were comparatively more abundant in postgastrectomy patients (online supplementary tables S10 and S11). DCA is a microbiome-produced carcinogen in liver cancer<sup>44</sup> and CRC.<sup>15 16 45</sup> Obesity studies have raised concerns regarding microbiome changes and secondary bile acids increment following gastrectomy, as well as their link to CRC occurrence.<sup>46 47</sup> Patients with gastric cancer were also reported to be at an increased risk of developing metachronous CRC.<sup>13 14</sup>

Although the mechanism for metachronous CRC onset after gastrectomy may not be similar to sporadic cancer, we observed higher abundances of several CRC-enriched microbes (eg, F. nucleatum and Atopobium parvulum) in the gastrectomy group. F. nucleatum has been suggested to mediate the early steps of carcinogenesis,<sup>15</sup> through FadA adhesion to the epithelium, activation of  $\beta$ -catenin signalling<sup>48</sup> and infiltration of myeloid cells into the tumour microenvironment.<sup>49</sup> Thus, enrichment of *F. nucleatum* in the total gastrectomy group is worth noting. In addition, A. parvulum has been associated with multiple polypoid adenomas and intramucosal carcinoma.<sup>15 50</sup> Enrichment of these species suggests a form of dysbiosis, which can lead to CRC development after gastrectomy. In contrast, Parvimonas micra and Peptostreptococcus stomatis, which are also associated with CRC,<sup>51</sup> were not significantly enriched in postgastrectomy patients (online supplementary tables S10 and S11). This may be partly explained by their relative abundances being high only in the presence of carcinomas.<sup>15</sup>

Of note is also our observation on higher branched-chain amino acids levels and species richness after gastrectomy. Branched-chain amino acids are elevated in plasma and tissue of gastric cancer<sup>52</sup> and CRC.<sup>53</sup> Additionally, increased species richness in CRC has been partly attributed to a greater abundance of oral microbes.<sup>17</sup> Our findings question the supposed association between decreased species richness and intestinal dysbiosis.<sup>54</sup> Altogether, they indicate that although the mechanism of metachronous CRC in postgastrectomy patients may not be exactly the same as that of non-gastrectomy CRC, the similar microbiome contribution can be speculated in the cancer development.

We acknowledge that our study presents also some limitations. Even though our analysis was data-driven, it requires further validation. Future longitudinal or prospective studies with comprehensive medical records including health-related quality of life assessment (eg, based on Gastroenterology Quality of Life Index or Life After Gastric Surgery),<sup>55</sup> intestinal inflammation under colonoscopy, intestinal permeability and nutrition assessment may provide further evidence to support our hypothesis. Additionally, most of our postgastrectomy patients underwent Roux-en-Y reconstruction, so our findings might be representative of this specific reconstruction (online supplementary results and online supplementary table S18).

Our schematic hypothesis (figure 6) could be used as a framework for proof-of-concept studies that link the impact of microbiome alterations with patients' outcome after gastrectomy. Our findings are in many ways consistent with results from other gastrectomy studies. We also identified several microbial functions and metabolites that might correlate with postsurgical metabolism. To determine if the microbiome is indeed involved in CRC occurrence following gastrectomy, further follow-up prospective studies are required. Our analysis also underlines the importance for gastrectomy patients to undergo intensified surveillance such as colonoscopy for early detection of possible metachronous CRC occurrence. To our knowledge, this is the first report on microbiome alterations using metagenomics and metabolomics data analysis after gastrectomy, especially total gastrectomy, for gastric cancer treatment. The present findings may be used to complement a non-invasive method for postsurgical prognosis assessment.

#### Author affiliations

<sup>1</sup>School of Life Science and Technology, Tokyo Institute of Technology, Meguro-ku, Tokyo, Japan

<sup>2</sup>Research Fellow of Japan Society for the Promotion of Science, Tokyo, Japan <sup>3</sup>Division of Cancer Genomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan

<sup>4</sup>Endoscopy Division, National Cancer Center Hospital, Tokyo, Tokyo, Japan <sup>5</sup>Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan <sup>6</sup>Intestinal Microbiota Project, Kanagawa Institute of Industrial Science and Technology, Ebina, Kanagawa, Japan

<sup>7</sup>Transborder Medical Research Center, University of Tsukuba, Ibaraki, Japan <sup>8</sup>Department of Cancer Genome Informatics, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita, Osaka, Japan

Twitter Pande Putu Erawijantari @erawijantaript

**Acknowledgements** The authors would like to thank all participants, and their families, who participated in this study. The authors would like to thank Ms. Natsumi Sezawa and Ms. Manami Iwahara (National Cancer Center Research Institute, Japan), Ms. Yuka Ohara, Ms. Noriko Kagata and Ms. Kaori Igarashi (Institute for Advanced Biosciences, Keio University, Japan) for expert technical assistance.

**Contributors** PPE, SM, SY and TY contributed to study concept and design. SY, SS, TN, TS and YS collected clinical samples and information. SF performed metabolome quantification. PPE, SM, HS and TY performed bioinformatics analyses on metagenomic and metabolomic data. PPE, SM, SY and TY wrote the manuscript. SY, SS and TY gave critical revision of the manuscript for important intellectual content. SY and TY supervised the study. All authors read and approved the final manuscript.

Funding This work was supported by grants from the Japan Agency for Medical Research and Development (AMED) (JP18ek0109187 to SF, SY and TY; JP19gm1010009 to SF and JP19cm0106464 to SY and TY); the National Cancer Center Research and Development Fund (25-A-4, 28-A-4, 29-A-13 and 29-A-6 to YS, SF, SY and TY); JST (Japan Science and Technology Agency)-PRESTO (JPMJPR1537 to SF and JPMJPRI507 to TY); JST-ERATO (JPMJER1902 to SF); JST-AIP Acceleration Research (JPMJCR19U3 to SY and TY); JSPS (Japan Society for the Promotion of Science) KAKENHI (142558 and 22150002 to TY; 16H04901, 17H05654 and 18H04805 to SF); the Food Science Institute Foundation (to SF); the Program for the Advancement of Research in Core Projects under Keio University's Longevity Initiative (to SF); Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University (SY); Joint Research Project of the Institute of Medical Science, the University of Tokyo (to SY); the Takeda Science Foundation (to SY and SF): the Suzuken Memorial Foundation (to SY): the Yasuda Memorial Medical Foundation (to SY) and Yakult Bio-Science Foundation (to SY)

**Competing interests** SF and TY are founders of Metabologenomics. The company is focused on the design and control of the gut environment for human health. The company had no control over the interpretation, writing or publication of this work. The terms of these arrangements are being managed by Keio University and Tokyo Institute of Technology in accordance with its conflict of interest policies.

#### Patient consent for publication Not required.

**Ethics approval** The samples and clinical information used in this study were obtained under conditions of informed consent and with approval by the institutional review boards of each participating institute (National Cancer Center, 2013-244; Tokyo Institute of Technology, 2014018 and Keio University, Shonan Fujisawa Campus, 78).

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** The raw sequencing data reported in this paper have been deposited at the DNA Data Bank of Japan (DDBJ) Sequence Read Archive (DRA), Tokyo, Japan under accession numbers DRA007281, DRA008243, DRA006684 and DRA008156. The source codes describing all of the analysis performed for this paper are available online (https://github.com/yamada-lab/GastrectomyGC\_Microbiome).

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

## ORCID iDs

Pande Putu Erawijantari http://orcid.org/0000-0002-5173-6347 Sayaka Mizutani http://orcid.org/0000-0003-4168-6195 Hirotsugu Shiroma https://orcid.org/0000-0001-5507-4566 Satoshi Shiba http://orcid.org/0000-0001-5159-5719 Shinji Fukuda http://orcid.org/0000-0001-5161-9880 Shinichi Yachida https://orcid.org/0000-0001-5507-4566 Takuji Yamada http://orcid.org/0000-0002-9622-1849

## REFERENCES

- 1 Guyton K, Alverdy JC. The gut microbiota and gastrointestinal surgery. *Nat Rev Gastroenterol Hepatol* 2017;14:43–54.
- 2 Lederer A-K, Pisarski P, Kousoulas L, *et al*. Postoperative changes of the microbiome: are surgical complications related to the gut flora? A systematic review. *BMC Surg* 2017;17:125.
- 3 Gutiérrez-Repiso C, Moreno-Indias I, de Hollanda A, et al. Gut microbiota specific signatures are related to the successful rate of bariatric surgery. Am J Transl Res 2019;11:942–52.
- 4 Mondot S, Lepage P, Seksik P, *et al*. Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery. *Gut* 2016;65:954–62.
- 5 Bennett JMH, Mehta S, Rhodes M. Surgery for morbid obesity. *Postgrad Med J* 2007;83:8–15.
- 6 Penna M, Allum W. New treatments for gastric cancer: are they changing clinical practice? *Clinical Practice* 2013;10:649–59.
- 7 Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009;106:2365–70.
- 8 Graessler J, Qin Y, Zhong H, *et al*. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. *Pharmacogenomics J* 2013;13:514–22.
- 9 Palleja A, Kashani A, Allin KH, et al. Roux-En-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. *Genome Med* 2016;8:67.
- Aron-Wisnewsky J, Prifti E, Belda E, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut 2019;68:70–82.
- 11 Tseng C-H, Lin J-T, Ho HJ, *et al*. Gastric microbiota and predicted gene functions are altered after subtotal gastrectomy in patients with gastric cancer. *Sci Rep* 2016;6.
- 12 Lin X-H, Huang K-H, Chuang W-H, et al. The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy. PLoS One 2018;13:e0206930.
- 13 Eom BW, Lee H-J, Yoo M-W, et al. Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol 2008;98:106–10.
- 14 Ikeda Y, Saku M, Kawanaka H, *et al*. Features of second primary cancer in patients with gastric cancer. *Oncology* 2003;65:113–7.
- 15 Yachida S, Mizutani S, Shiroma H, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 2019;25:968–76.
- 16 Wirbel J, Pyl PT, Kartal E, et al. Meta-Analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 2019;25:679–89.
- 17 Thomas AM, Manghi P, Asnicar F, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med 2019;25:667–78.
- 18 Nishimoto Y, Mizutani S, Nakajima T, et al. High stability of faecal microbiome composition in guanidine thiocyanate solution at room temperature and robustness during colonoscopy. Gut 2016;65:1574–5.
- 19 Shin S, Saito E, Sawada N, et al. Dietary patterns and colorectal cancer risk in middleaged adults: A large population-based prospective cohort study. *Clinical Nutrition* 2018;37:1019–26.
- 20 Soga T, Ohashi Y, Ueno Y, *et al.* Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. *J Proteome Res* 2003;2:488–94.
- 21 Sunagawa S, Mende DR, Zeller G, et al. Metagenomic species profiling using universal phylogenetic marker genes. Nat Methods 2013;10:1196–9.
- 22 Truong DT, Franzosa EA, Tickle TL, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods 2015;12:902–3.
- 23 Chen T, Yu W-H, Izard J, et al. The human oral microbiome database: a web accessible resource for investigating oral microbe taxonomic and genomic information. Database 2010;2010:baq013.
- 24 Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013;31:814–21.

- 25 Franzosa EA, McIver LJ, Rahnavard G, et al. Species-Level functional profiling of metagenomes and metatranscriptomes. Nat Methods 2018;15:962–8.
- 26 Kanehisa M, Goto S. Kegg: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000;28:27–30.
- 27 Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011;12:R60.
- 28 Morgan XC, Tickle TL, Sokol H, *et al*. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol* 2012;13:R79.
- 29 Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. *PLoS Comput Biol* 2012;8:e1002687.
- 30 Noecker C, Eng A, Srinivasan S, *et al*. Metabolic model-based integration of microbiome taxonomic and metabolomic profiles elucidates mechanistic links between ecological and metabolic variation. *mSystems* 2016;1.
- 31 Radigan AE. Post-Gastrectomy: managing the nutrition fallout. *Pract Gastroenterol* 2004;28:63–79.
- 32 Ilhan ZE, DiBaise JK, Isern NG, et al. Distinctive microbiomes and metabolites linked with weight loss after gastric bypass, but not gastric banding. Isme J 2017;11:2047–58.
- 33 Kong L-C, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 2013;98:16–24.
- 34 Röttjers L, Faust K. From hairballs to hypotheses–biological insights from microbial networks. FEMS Microbiol Rev 2018;42:761–80.
- 35 Dai Z-L, Wu G, Zhu W-Y. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. *Front Biosci* 2011;16:1768–86.
- 36 Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. *Nat Rev Gastroenterol Hepatol* 2012;9:590–8.
- 37 Quercia I, Dutia R, Kotler DP, et al. Gastrointestinal changes after bariatric surgery. Diabetes Metab 2014;40:87–94.
- 38 Celiker H. A new proposed mechanism of action for gastric bypass surgery: air hypothesis. *Med Hypotheses* 2017;107:81–9.
- 39 Lim J, Yoo M-W, Kang SY, et al. Long-Term changes in the metabolic and nutritional parameters after gastrectomy in early gastric cancer patients with overweight. Asian J Surg 2019;42:386–93.
- 40 Jun J-H, Yoo JE, Lee JA, *et al*. Anemia after gastrectomy in long-term survivors of gastric cancer: a retrospective cohort study. *International Journal of Surgery* 2016;28:162–8.
- 41 Degnan PH, Taga ME, Goodman AL. Vitamin B 12 as a modulator of gut microbial ecology. *Cell Metab* 2014;20:769–78.
- 42 Liu H, Hu C, Zhang X, *et al.* Role of gut microbiota, bile acids and their cross-talk in the effects of bariatric surgery on obesity and type 2 diabetes. *J Diabetes Investig* 2018;9:13–20.
- 43 Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241–59.
- 44 Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-Induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97–101.
- 45 Ajouz H, Mukherji D, Shamseddine A. Secondary bile acids: an underrecognized cause of colon cancer. *World J Surg Oncol* 2014;12:164.
- 46 Hull MA, Markar SR, Morris EJA. Cancer risk after bariatric surgery is colorectal cancer a special case? *Nat Rev Gastroenterol Hepatol* 2018;15:653–4.
- 47 Mackenzie H, Markar SR, Askari A, *et al*. Obesity surgery and risk of cancer. *Br J Surg* 2018;105:1650–7.
- 48 Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-Cadherin/β-Catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195–206.
- 49 Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207–15.
- 50 Kasai C, Sugimoto K, Moritani I, et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep 2016;35:325–33.
- 51 Yu J, Feng Q, Wong SH, *et al*. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. *Gut* 2017;66:70–8.
- 52 Chan AWet al. Potential role of metabolomics in diagnosis and surveillance of gastric cancer. WJG 2014;20:12874–82.
- 53 Denkert C, Budczies J, Weichert W, *et al*. Metabolite profiling of human colon carcinoma deregulation of TCA cycle and amino acid turnover. *Mol Cancer* 2008;7:72.
- 54 Le Chatelier E, Nielsen T, Qin J, *et al*. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013;500:541–6.
- 55 Shan B, Shan L, Morris D, et al. Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma. J Gastrointest Oncol 2015;6:544–60.